Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
July 18, 2008
By: Gil Roth
President, Pharma & Biopharma Outsourcing Association
I had a pretty good angle for the original draft of this editorial. As part of my work on our annual Top Companies issue, I have to read a lot of annual reports and SEC filings. There’s a wealth of information to be found in these documents, of course. At times it takes some detective work to figure out the connections among various line items. I don’t pretend to know everything that’s in them, but I end up making some pretty good observations, both about what companies say and what they don’t say. For instance, I find it fascinating that, while major pharma companies will passingly refer to “some third party suppliers” in the manufacturing segments of their 10-K statements, small biopharmas tend to detail every CMO with whom they work. It’s that question of what’s “material” to the shareholders, and contract services don’t top the list for companies with enormous manufacturing networks. Of course, those giant networks come with their own set of costs, and they’re quite material to the shareholders. Reading all those reports this year, I was struck by the number of major companies that are avowedly “rationalizing” their manufacturing and R&D networks (after having fired tons of salespeople). My original premise for this column was to run a mix-and-match of companies and the names of their restructuring programs. I don’t have a theory yet as to why some companies come up with “Project Impact,” ”Forward,” and “Plan To Win,” while others simply refer to it as their restructuring program; if any of you can offer one, I’d be glad to hear it. Still, I thought it’d be funny to goof on that corporate-speak mentality that tries to dress up a program of plant shutdowns, lab spinoffs and massive firings with a baseball cap-worthy brand name. I also had a digression about the two NJ-based companies that had a “Productivity Transformation Initiative” and a “Productivity Transformation Program,” wondering who cribbed from whom. Then I reflected on the interview I conducted with Tony Maddaluna, part of whose job is helping Pfizer’s manufacturing division go from 100 plants down to 43. Most of our conversation made it into the article, but there were a few passages that the company asked me not to run. When I looked back over my original transcript and then at my spreadsheet of fancy restructuring names, I understood where they were coming from. I hadn’t thought about it before, but there’s a real problem in talking about these plans. No matter how well intentioned the plan is, nor how much you try to avoid it, you make the people sound like numbers, or components of the facility that’s being shut down, or “total savings, mainly through attrition.” Tony took great pains to convey that it’s never easy to close a factory (and I don’t just mean because of labor laws), especially since the company is in the process of closing the one where he cut his teeth as a plant manager. Still, there’s something in the way people (with jobs) talk about this topic that can’t help but be heard as callous. There’s no easy way to talk about firing thousands of people. (Even if you promise to start with management, Mr. Hassan.) So no jokes from me, this time around.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !